Q9NZQ7 (PD1L1_HUMAN) Homo sapiens (Human)
Programmed cell death 1 ligand 1 UniProtKBInterProSTRINGInteractive Modelling
It is possible new templates exist for this target since these models were created.
Available Structures
65 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Complex of PD-L1 with VHH1 |
Heteromer | 100.0 | 1×MG; | |||
| Crystal structure of human PD-L1 with monoclonal antibody avelumab |
Heteromer | 100.0 | ||||
| Crystal structure of human PD-L1 in complex with high affinity PD-1 mutant |
Heteromer Q15116; | 100 | 1×CL; | |||
| Crystal Structure of the PD-1/PD-L1 Complex |
Heteromer Q02242; | 100 | ||||
| Crystal strucutre of PD-L1 and 3ONJA protein |
Heteromer | 100 | ||||
| Human PD-L1 bound to a macrocyclic peptide which blocks the PD-1/PD-L1 interaction |
Heteromer | 100.0 | ||||
| Crystal structure of the complex between the extracellular domains of mouse PD-1 mutant and human P… |
Heteromer Q02242; | 100.0 | ||||
| Crystal strucutre of PD-L1 and DBL2_02 designed protein binder |
Heteromer Q04338; | 99.05 | ||||
| Crystal structure of ALPN-202 (engineered CD80 vIgD) in complex with PD-L1 |
Heteromer P33681; | 100 | 2×NAG; 3×NAG; | |||
| Crystal strucutre of PD-L1 and the computationally designed DBL1_03 protein binder |
Heteromer | 100.0 | 1×ARG; | |||
| Ex silico engineering of cystine-dense peptides yielding a potent bispecific T-cell engager |
Heteromer | 100 | 1×GOL; 1×NAG; 1×SO4; 1×NA; | |||
| The structure of the bispecific antibody targeted PD-L1 and 4-1BB |
Heteromer | 99.14 | ||||
| Structure of PDL1 in complex with FP28135, a Helicon Polypeptide |
Heteromer | 100 | 4×EDO; 1×WHL; | |||
| Complex of PD-L1 with VHH6 |
Heteromer | 99.14 | 3×PEG; 1×ACY; 1×OXM; 2×EDO; 1×FMT; 1×PG4; | |||
| Crystal structure of PD-L1 in complex with a VHH |
Heteromer | 100 | 3×EDO; | |||
| Complex structure of JS003 and PD-L1 |
Heteromer | 100 | ||||
| PD-L1 in complex with durvalumab |
Heteromer | 99.14 | ||||
| PD-L1 in complex with BMS-936559 Fab |
Heteromer | 100 | ||||
| PD-L1 in complex with atezolizumab |
Heteromer | 99.11 | ||||
| Structure of PDL1 in complex with FP28136, a Helicon Polypeptide |
Heteromer | 100 | 1×WHL; | |||
| Crystal structure of PD-L1 complexed with a nanobody at 1.7 Angstron resolution |
Heteromer | 100 | 2×NA; 3×CL; 1×SO4; | |||
| Structure of the complex of human programmed death-1 (PD-1) and its ligand PD-L1. |
Heteromer Q15116; | 100 | 1×NA; | |||
| Crystal structure of PD-L1 complexed with atezolizumab fab at 2.9A |
Heteromer | 100.0 | ||||
| Structure of PDL1 in complex with FP28132, a Helicon Polypeptide |
Heteromer | 100 | 1×NH2; 1×WHL; | |||
| Structure of S79 Fab in complex with IgV domain of human PD-L1 |
Heteromer | 100 | 1×CL; 3×GOL; 6×SO4; | |||
| Design, modification, evaluation and cocrystal studies of novel phthalimides regulating PD-1/PD-L1 … | homo-8-mer | 100 | 4×8H7; | |||
| Structure of PD-L1/small-molecule inhibitor complex | homo-4-mer | 100 | 2×8J8; | |||
| Dimeric Structure of PD-L1 | homo-2-mer | 100 | ||||
| CRYSTAL STRUCTURE OF HUMAN PD-L1 | homo-2-mer | 100 | 1×CL; | |||
| Structure of PD-L1 | homo-2-mer | 100 | ||||
| PD-L1 IgV domain V76T with fragment | homo-2-mer | 99.13 | 4×SO4; | |||
| Structure of PD-L1/small-molecule inhibitor complex | homo-2-mer | 100 | 1×8HW; | |||
| Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor | homo-2-mer | 100 | 1×8YZ; 1×EDO; | |||
| Co-crystal structure of PD-L1 with low molecular weight inhibitor | homo-2-mer | 100 | 1×WEW; 2×CL; 2×SO4; | |||
| Solubilizer tag effect on PD-L1/inhibitor binding properties for m-terphenyl derivatives | homo-2-mer | 100 | 1×WEW; 2×CL; 2×SO4; | |||
| Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor | homo-2-mer | 100 | 1×6GX; | |||
| Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor | homo-2-mer | 100 | 1×EDO; 1×JQT; | |||
| Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor | homo-2-mer | 100 | 1×6GZ; | |||
| PD-L1 IgV domain V76T with fragment | homo-2-mer | 99.14 | 1×KW7; | |||
| Discovery of Novel Small-molecule Inhibitors of PD-1/PD-L1 Axis that Promotes PD-L1 Internalization… | homo-2-mer | 100 | 1×HOU; | |||
| Structure of human Programmed cell death 1 ligand 1 (PD-L1) with inhibitor | homo-2-mer | 100 | 1×TK2; | |||
| Co-crystal structure of human PD-L1 complexed with Compound A | homo-2-mer | 100 | 1×R81; | |||
| Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 | homo-2-mer | 100 | 1×A1H56; | |||
| Discovery and Crystallography Study of Novel Oxadiazole Analogs as Small Molecule PD-1/PD-L1 inhibi… | homo-2-mer | 100 | 1×AU9; | |||
| Structure of human Programmed cell death 1 ligand 1 (PD-L1) with inhibitor | homo-2-mer | 100 | 1×KDW; | |||
| Co-crystal strucutre of PD-L1 with low molecular weight inhibitor | homo-2-mer | 100 | 1×VVH; 1×SO4; | |||
| PD-L1 IgV domain V76T with fragment | homo-2-mer | 99.14 | 1×KWA; | |||
| Co-crystal structure of PD-L1 with low molecular weight inhibitor | homo-2-mer | 100 | 1×X1Q; | |||
| Discovery of Novel PD-L1 Inhibitors That Induce Dimerization and Degradation of PD-L1 Based on Frag… | homo-2-mer | 100 | 1×I7M; | |||
| Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor | homo-2-mer | 100 | 1×UGZ; | |||
| PD-L1 IgV domain bound to fragment | homo-2-mer | 99.14 | 1×22L; | |||
| IgV-V76T BMS compound 105 | homo-2-mer | 99.14 | 1×KSD; | |||
| Co-crystal strucutre of PD-L1 with low molecular weight inhibitor | homo-2-mer | 100 | 1×VYC; | |||
| Crystal Structure of the PD-L1 | monomer | 100 | ||||
| Complex structure of durvalumab-scFv/PD-L1 | monomer | 100.0 | ||||
| Structure of human PD-L1 in complex with inhibitor | monomer | 100 | ||||
| Structure of human PD-L1 in complex with inhibitor | monomer | 100 | ||||
| PD-1 binding domain from human PD-L1 | monomer | 99.14 | ||||
| Structure of human PD-L1 in complex with macrocyclic inhibitor | monomer | 100 | ||||
| PD-L1 IgV domain complex with macro-cyclic peptide | monomer | 99.14 | ||||
| Structure of PDL1 in complex with FP30790, a Helicon Polypeptide | monomer | 100 | 1×NH2; 1×WHL; | |||
| Structure of human PD-L1 in complex with inhibitor | monomer | 100 | 3×ACT; 2×GOL; | |||
| Structure of human PD-L1 in complex with inhibitor | monomer | 100 | ||||
| Structure of the transmembrane domain of human PD-L1 | monomer | 93.22 | ||||
| membrane-bound PD-L1-CD | monomer | 100 | ||||
2 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 7xae.1.A | monomer | 0.81 | 100.00 | |||
| 4k9e.1.A | monomer | 0.57 | 14.72 | |||
8 SWISS-MODEL models built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 8aom.1.A | monomer | 0.76 | 99.09 | |||
| Isoform 2 | 5ius.1.B | monomer | 0.59 | 99.09 | |||
| Isoform 2 | 7dcv.1.A | monomer | 0.58 | 93.22 | |||
| Isoform 2 | 6dkp.1.E | monomer | 0.51 | 21.69 | |||
| Isoform 3 | 7xad.4.A | monomer | 0.82 | 100.00 | |||
| Isoform 3 | 9dn4.1.A | monomer | 0.52 | 17.61 | |||
| Isoform 4 | 7xae.1.A | monomer | 0.82 | 99.13 | |||
| Isoform 4 | 9dn4.1.A | monomer | 0.56 | 15.98 | |||